Modulation of radiation biomarkers in a randomized phase II study of 131I-MIBG with or without radiation sensitizers for resistant/relapsed neuroblastoma.

Kevin M. Campbell,Susan Groshen,Araz Marachelian,Sharmistha Pal,Daphne A. Haas-Kogan,Mark D. Kellogg,Angela Clare Evans,Matthew A. Coleman,Julie R. Park,Meaghan Granger,Katherine K. Matthay,Steven G. DuBois

Modulation of radiation biomarkers in a randomized phase II study of 131I-MIBG with or without radiation sensitizers for resistant/relapsed neuroblastoma.

2020

Kevin M. Campbell
Susan Groshen
Araz Marachelian
Sharmistha Pal
Daphne A. Haas-Kogan
Mark D. Kellogg
Angela Clare Evans
Matthew A. Coleman
Julie R. Park
Meaghan Granger
Katherine K. Matthay
Steven G. DuBois

e22514Background: 131I-metaiodobenzylguanidine (MIBG), a radiopharmaceutical agent, has demonstrated efficacy as a single agent for patients with neuroblastoma. Recently, trials have focused on MIB...

Keywords:

Oncology
Phases of clinical research
Internal medicine
131i mibg
Biomarker (medicine)
Pathology
Medicine
Radiation sensitizers
Relapsed Neuroblastoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations